FAK and paxillin, two potential targets in pancreatic cancer

Rajani Kanteti; Surinder K. Batra; Frances E. Lennon; Ravi Salgia

doi:10.18632/oncotarget.8040

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

FAK and paxillin, two potential targets in pancreatic cancer

Rajani Kanteti, Surinder K. Batra, Frances E. Lennon and Ravi Salgia _

PDF | HTML | How to cite

Oncotarget. 2016; 7:31586-31601. https://doi.org/10.18632/oncotarget.8040

Metrics: PDF 3544 views | HTML 5413 views | ?

Abstract

Rajani Kanteti1, Surinder K. Batra2, Frances E. Lennon1 and Ravi Salgia3

1 Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA

2 Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA

3 Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA

Correspondence to:

Ravi Salgia, email:

Keywords: FAK, paxillin, pancreatic cancer, integrins, P53

Received: October 22, 2015 Accepted: February 11, 2016 Published: March 13, 2016

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a devastating cancer in large part due to late diagnosis and a lack of effective screening tests. In spite of recent progress in imaging, surgery and new therapeutic options for pancreatic cancer, the overall five-year survival still remains unacceptably low. Numerous studies have shown that focal adhesion kinase (FAK) is activated in many cancers including PDAC and promotes cancer progression and metastasis. Paxillin, an intracellular adaptor protein that plays a key role in cytoskeletal organization, connects integrins to FAK and plays a key role in assembly and disassembly of focal adhesions. Here, we have reviewed evidence in support of FAK as a potential therapeutic target and summarized related combinatorial therapies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8040

Publication Alerts

Reviews:

FAK and paxillin, two potential targets in pancreatic cancer

Abstract